Loading, Please Wait...
RICHLAND, Wash., Jan. 29, 2019 (GLOBE NEWSWIRE) -- – Isoray, Inc. (NYSE American: ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment options throughout the body, today announced that Hollings Cancer Center at the Medical University of South Carolina (MUSC) has successfully completed the world’s first prostate cancer surgery using the pioneering Blu Build real-time Cesium-131 brachytherapy (internal radiation therapy) delivery system.
Dr. David T. Marshall, a professor of Radiation Oncology and Urology, and medical director of the Clinical Trials Office at the Hollings Cancer Center, performed the surgery on October 26, 2018. “No two patients are exactly alike. What Blu Build provides physicians is a real-time means to individually customize and deliver a precise placement of Cesium-131 brachytherapy seeds tailored to the patient’s anatomy and cancer as the physician is seeing it in the operating room at the time of surgery,” Dr. Marshall said. Since the successful completion of the first surgery, Dr. Marshall has used Blu Build to treat 12 additional prostate cancer patients.
“Here at Hollings Cancer Center, we are proud to continue our legacy as innovators dedicated to bringing the very best in medical advancements and care to our patients,” concluded Dr. Marshall.
Isoray’s disposable, single use, next-generation device is also unique in that it is the first to be handheld offering a new level of maneuverability.
Blu Build is believed to be the first new delivery system designed specifically for prostate brachytherapy in years. The delivery system conveys additional benefits as it enables doctors to deliver a high radiation dose to the targeted prostate cancer and limits the impact on the surrounding areas compared to other treatment options.
Isoray CEO Lori Woods said this is an important development for prostate cancer patients and physicians. “Blu Build provides each patient personalized treatment for their specific situation with the unique treatment benefits of Cesium-131 brachytherapy. This is an important step forward in prostate cancer treatment.”
Isoray is the only producer of Cesium-131 brachytherapy, which expands internal radiation treatment for prostate and difficult to treat brain, gynecological, lung, head and neck, esophageal, and abdominal wall cancers.
Isoray, Inc., through its subsidiary, IsoRay Medical, Inc. is the sole producer of Cesium-131 brachytherapy seeds, which are expanding brachytherapy options throughout the body. Learn more about this innovative Richland, Washington company and explore the many benefits and uses of Cesium-131 by visiting www.isoray.com. Join us on Facebook/IsoRay. Follow us on Twitter @IsoRay.
About Hollings Cancer Center
The Hollings Cancer Center at the Medical University of South Carolina is a National Cancer Institute-designated cancer center and the largest academic-based cancer research program in South Carolina. The cancer center comprises more than 100 faculty cancer scientists and 20 academic departments. It has an annual research funding portfolio of more than $40 million and a dedication to reducing the cancer burden in South Carolina. Hollings offers state-of-the-art diagnostic capabilities, therapies and surgical techniques within multidisciplinary clinics that include surgeons, medical oncologists, radiation therapists, radiologists, pathologists, psychologists and other specialists equipped for the full range of cancer care, including more than 200 clinical trials. For more information, visit http://www.hollingscancercenter.org
Safe Harbor Statement
Statements in this news release about Isoray’s future expectations, including: the advantages of Cesium-131 and its delivery systems, including the Blu Build delivery system, whether demand for and use of the Blu Build delivery system will occur as anticipated, the viability and efficacy of the Blu Build delivery system, continued positive industry data fueling renewed interest in brachytherapy patient results from use of the Blu Build delivery system, and all other statements in this release, other than historical facts, are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 (“PSLRA”). This statement is included for the express purpose of availing Isoray, Inc. of the protections of the safe harbor provisions of the PSLRA. It is important to note that actual results and ultimate corporate actions could differ materially from those in such forward-looking statements based on such factors as physician acceptance, training and use of our products, including the Blu Build delivery system, our ability to manufacture the Blu Build delivery system in sufficient quantities to meet demand within required delivery time periods while meeting our quality control standards, whether ongoing patient results with the Blu Build delivery system are favorable, whether we, our distributors and our customers will successfully obtain and maintain all required regulatory approvals and licenses to market, sell and use our products in its various forms, changes in laws and regulations applicable to our products, the use of competitors’ delivery systems in lieu of our Blu Build delivery system, and other risks detailed from time to time in Isoray’s reports filed with the U.S. Securities Exchange Commission. Unless required to do so by law, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Contact Media and Public Relations: Sharon Schultz (302) 539-3747 Investor Relations: Mark Levin (501) 255-1910